
Nanovelos S.A.
Research and experimental development in natural sciences and engineering
Overview
Nanovelos is a biotechnology company specializing in the use of nanotechnology for oncological therapies. It develops polysaccharide-based drug carriers aimed at precise drug delivery for cancer treatment, specifically working on an effective drug using epirubicin (PolEpi) for ovarian cancer therapy. The company's technology aims to enhance treatment efficacy while minimizing adverse effects on patients.
Financials
Revenue history (in k)
Financial insights
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
- The statement flags a going concern risk. Zarząd wskazuje znaczącą niepewność dotyczącą kontynuacji działalności, związaną z ryzykiem projektów badawczo-rozwojowych i koniecznością pozyskiwania finansowania.
From the notes
| Profit allocation | Loss to be covered | |
| Capital expenditure | $68,106 | |
| Shareholders |
|
Filing timeliness
1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.
- 202514/07/2026
- 202414/07/2025
- 202305/08/2024
- 202206/07/2023
- 202130/06/2022
- 202002/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Research on drug carriers
- Development of polysaccharide carriers
- Drug delivery systems
- Development of an anticancer drug
- Oncology therapies
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
- Analytics and marketing
- Google Analytics
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2013-04-25.
14 1090 1056 0000 0001 3508 2090
88 1090 1056 0000 0001 2050 0979
54 1090 1056 0000 0001 4676 5214
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 2, 2018 | Call to creditors |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,930$3,930 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,841$3,841 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,751$3,751 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-06-01 | Preclinical and clinical studies of innovative nanoformulations of anticancer drugs. | $2.5M$2,480,610 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medesto sp. z o.o. | $120,911.45 | medesto.com.pl | ||
| WPD Pharmaceuticals S.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| Onconick sp. z o.o. | $39,587.95 | onconick.com | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| Stenocoat sp. z o.o. | $36,665.21 | stenocoat.com | ||
| Cannamedai S.A. | $28,203.90 | cannamedai.com | ||
| Inventro S.A. | $25,971.59 | inventro.co | ||
| Oncotherics Poland S.A. | $7,565.33 | oncotherics.com | ||
| Cannabibs sp. z o.o. | $5,897.47 | cannabibs.eu |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-31 | Switch to PKD 2025 (7 PKD 2007 codes → 5 PKD 2025 codes) | |
| 2025-01-24 | Share capital increase (981,537.50 PLN → 1,004,320.80 PLN) | |
| 2023-11-14 | Share capital increase (681,537.50 PLN → 981,537.50 PLN) | |
| 2023-06-12 | Share capital increase (181,537.50 PLN → 681,537.50 PLN) | |
| 2022-12-07 | Share capital increase (178,720.50 PLN → 181,537.50 PLN) |
FAQ
Last updated: 2026-07-17